Publications by authors named "M Bonfichi"

Claim this Profile
R
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Maurizio Bonfichi

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Armando Santoro, Rita Mazza, Michele Spina, Catello Califano, Giorgina Specchia, Maurizio Bonfichi

Ann Hematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.
Alessia Bari, Raffaella Marcheselli, Stefano Sacchi, Alessandro Re, Chiara Pagani, Maurizio Bonfichi

Ann Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
Vittorio Stefoni, Miriam Marangon, Alessandro Re, Arben Lleshi, Maurizio Bonfichi

Haematologica· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi

Blood Adv· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis